Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations. 
X
Active Filter(s):
Details:
2-deoxy-D-glucose (2-DG), reduces the multiplicity of the SARS-CoV-2 virus, alleviates cells from infection-induced cytopathic effect (CPE) and cell death. 2-DG manufactured by Dr. Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DG.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: BDR Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2021
Details:
Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufacture the drug.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Lee Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 09, 2021
